Atossa Therapeutics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more
Atossa Therapeutics Inc (YAG2) - Total Liabilities
Latest total liabilities as of September 2025: €8.22 Million EUR
Based on the latest financial reports, Atossa Therapeutics Inc (YAG2) has total liabilities worth €8.22 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Atossa Therapeutics Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Atossa Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Atossa Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Atossa Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Park City Group Inc
F:PJ4A
|
Germany | €5.44 Million |
|
Fenix Resources Limited
F:4ER
|
Germany | €186.70 Million |
|
Cogelec SA
PA:ALLEC
|
France | €95.77 Million |
|
Hanover Bancorp Inc
NASDAQ:HNVR
|
USA | $2.18 Billion |
|
Nordhealth AS
OL:NORDH
|
Norway | Nkr9.97 Million |
|
LuxUrban Hotels Inc. 13.00% Series A Cumulative Redeemable Preferred Stock
NASDAQ:LUXHP
|
USA | $289.20 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Atossa Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Atossa Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Atossa Therapeutics Inc (2016–2024)
The table below shows the annual total liabilities of Atossa Therapeutics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €4.97 Million | -5.14% |
| 2023-12-31 | €5.24 Million | -5.96% |
| 2022-12-31 | €5.57 Million | +78.12% |
| 2021-12-31 | €3.13 Million | -80.05% |
| 2020-12-31 | €15.67 Million | +1074.91% |
| 2019-12-31 | €1.33 Million | -54.25% |
| 2018-12-31 | €2.92 Million | +137.92% |
| 2017-12-31 | €1.23 Million | +17.01% |
| 2016-12-31 | €1.05 Million | -- |